Literature DB >> 25784816

Single-nucleotide polymorphisms of microRNA processing machinery genes are associated with risk for gastric cancer.

Ying Xie1, Yingnan Wang1, Yuefei Zhao1, Zhanjun Guo1.   

Abstract

Recent studies demonstrate that microRNA-related single-nucleotide polymorphisms (miR-SNPs) are associated with the development of numerous human cancers. In this study, we investigated six miR-SNPs in microRNA processing machinery genes, including rs11077 of the XPO5 gene, rs14035 of the RAN gene, rs3742330 of the Dicer gene, rs9623117 of the TNRC6B gene, rs197412 of the GEMIN3 gene, and rs2740348 of the GEMIN4 gene, in gastric cancer patients and subsequently evaluated their potential roles in gastric cancer risk in a case control study. The results indicate that the C/C genotype of rs14035 from RAN, the A/A genotype of rs3742330 from Dicer, and the T/T genotype of rs9623117 from TNRC6B are significantly associated with gastric cancer risk. In conclusion, these miR-SNPs can be used as predictive biomarkers in gastric cancer.

Entities:  

Keywords:  cancer risk; gastric cancer; miR-SNPs

Year:  2015        PMID: 25784816      PMCID: PMC4356688          DOI: 10.2147/OTT.S79150

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Gastric cancer (GC) is the fourth-most-common cancer and the second leading cause of cancer-related deaths worldwide;1,2 in addition, nearly two-thirds of GCs occur in developing regions.3 As a multifactorial disease, both environmental factors and genetic factors contribute to the etiology of this disease.4,5 Although much treatment progress has been achieved in recent years, the prognosis of GC remains poor due to the delay in diagnosis.6 MicroRNAs (miRNAs) are RNA molecules with lengths of ~22 nucleotides; they can act as posttranscriptional regulators in mRNA expression, and they regulate a variety of physiological and developmental processes, including the development and progression of numerous cancers.7–13 In GC, miRNAs can serve as biomarkers for both diagnosis and therapeutic targets.14–17 In miRNA processing, long primary transcripts of miRNAs (pre-miRNAs) are synthesized by RNase II in the nucleus, and they are cut into an ~70 nt hairpin precursor by RNase III Drosha and by the double-stranded RNA-binding protein DiGeorge syndrome critical region 8 (DGCR8). These precursors are exported to the cytoplasm, are processed by exportin-5 (XPO5) and RAN-GTPase (RAN), and are further diced into ~22 nt miRNA duplexes by the RNase III Dicer gene, which cooperates with the transactivation response RNA-binding protein and the Argonaute protein family. MiRNA duplexes are then assembled into the miRNA-induced silencing complex (miRISC), which contains GEMIN3 and GEMIN4. The miRISC will select one strand as the mature miRNA, and it guides the mature miRNAs to their target mRNA sites.18–23 MiRNA-related single nucleotide polymorphisms (miR-SNPs), which are defined as single-nucleotide polymorphisms (SNPs) in miRNA genes at the miRNA binding site and in miRNA processing machinery, can modulate miRNA and target gene expression to influence cancer development, promote therapeutic efficacy, and affect a patient’s prognosis.23–26 The miRNA machinery genes are linked to the development, progression, and prognosis of several cancer types, including ovarian and colorectal cancers, melanoma, and T-cell lymphoma.27–30 However, the role of the miRNA processing machinery genes in GC remains uncertain. In the present study, we genotyped six miR-SNPs in the miRNA processing machinery genes, including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348) in GC patients to evaluate the relationships of these genes with risk for development of GC.

Materials and methods

Sample collection and DNA extraction

Blood samples were collected from GC patients who underwent GC resection at the Department of General Surgery at the Fourth Hospital of Hebei Medical University from 2007–2008. Blood samples were also collected from normal controls without a history of any cancer. Genomic DNA was immediately extracted using the Wizard® Genomic DNA Purification Kit (Promega Corporation, Fitchburg, WI, USA) and was stored at −20°C. All procedures were supervised and approved by the Human Tissue Research Committee of the Fourth Hospital of Hebei Medical University. Written consent was obtained from all the patients and healthy controls enrolled in this study.

Genotyping of miR-SNPs

The miR-SNPs of the miRNA processing gene, including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348), according to the National Center for Biotechnology Information (NCBI) SNP database (http://www.ncbi.nlm.nih.gov/snp/), were genotyped using the polymerase chain reaction (PCR)–ligase detection reaction assay with the primers and probes listed in Table 1. PCR was performed with the PCR Master Mix Kit according to the manufacturer’s instructions (Promega, Madison, WI, USA). Ligation was performed using the different probes that were matched to the miR-SNPs, and the ligated products were separated using the ABI PRISM Genetic Analyzer 3730XL (Applied Biosystems, Foster City, CA, USA) to access the length differences of the ligated products.
Table 1

All the primers and probes used for genotyping of miR-SNPs

Geners NCBIPrimer sequenceProbe sequence
XPO5rs11077(A/C)F GAATCTGGTCACCTGATGGGAS1 GTACCTCCAAGGACCAGGGCTGGGA
R GTGCCTGAGTGGACCTTGAGS2 TTTGTACCTCCAAGGACCAGGGCTGGGCS3 AGTCTTTAGTGCTAACATCCCCTTT
RANrs14035(C/T)F GCACTTGCTCAAAATCTGTGAS1 TTTTAGTAATCATGTTTTAATGTAGAACC
R TAACAGCAAGAATTCCCAACCCTS2 TTTTTTTAGTAATCATGTTTTAATGTAGAAS3 TCAAACAGGATGGAACATCAGTGGATTT
GEMIN4rs2740348(G/C)F TTGCCTCTGAGAAGAAGTGGS1 TTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAC
R GACTCAGGGATGGCTCTGTCS2 TTTTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAGS3 AGCCAGACTTGGTGTTGAGGCTGCTTTTTTT
TNRC6Brs9623117(C/T)F TTTCT GTCTCCTCCTATCCATS1 TCTCCCTGTTACTCTTAAGTAGTGC
R CATTAGTTTAGCCAACAAGGTS2 TTTTCTCCCTGTTACTCTTAAGTAGTGTS3 CTCCTTTCCCCATCCACCCCATCTC
GEMIN3rs197412(T/C)F TAGAGAAACCTGTGGAAATCAS1 TTTTATGGTTTTGTGAGAAATAAAGTTAC
R GAAGAGGTTCTTGAGCTGTAAS2 TTTTTTTATGGTTTTGTGAGAAATAAAGTTATS3 TGAACAGAGAGTCCCTGTGTTGGCATTT
Dicerrs3742330(A/G)F AAAGGTATCAAGGTCTCAGTTTGS1 TTTTTTTTTTCAATCTTGTGTAAAGGGATTAGA
R CTGCAGAGGATCACTGGAATCS2 TTTTTTTTTTTTTCAATCTTGTGTAAAGGGATTAGGS3 CACCCTAACAGAGCAAGATCCAATATTTTTT

Notes: F: represents forward primer for PCR; R: represents reverse primer for PCR; S1 and S2 represent probes match to different allele of the SNP; S3 represents probes downstream of the SNP.

Abbreviations: NCBI, National Center for Biotechnology Information; PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism.

Statistical analysis

The χ2 test was applied to analyze dichotomous variables, such as the presence or absence of an individual SNP in patients and healthy controls. The odds ratios and 95% confidence intervals (CI) were calculated using an unconditional logistic regression model. All of the statistical analyses were performed with the SPSS version 18.0 software package (IBM Corporation, Armonk, NY, USA). A P-value <0.05 was considered statistically significant.

Results

A total of 137 GC patients and 142 healthy controls were included in this study. The clinical characteristics of the cases and controls are listed in Table 2. Six miR-SNPs were detected from the blood samples of the healthy controls and GC patients.
Table 2

Clinical characteristics in patients with gastric cancer and controls

CharacteristicCaseControlP-value
Sex0.959
 Male99103
 Female3839
Age (years)0.598
 ≤606866
 >606976
Clinical stage
 I + II47
 III + IV90
Size of tumor(diameter)
 ≤5 cm73
 >5 cm64
Degree of differentiation
 Highly + moderately88
 Poorly + undifferentiated49
Intravascular tumor emboli
 No100
 Yes37
Tumor location
 Upper third49
 Middle third43
 Lower third45
Lymph node metastasis
 N042
 N131
 N231
 N333
Postoperative chemotherapy
 No64
 Yes73
When individual SNPs were compared between GC patients and controls in terms of their distribution frequency, statistically significant increases for the C/C genotype of rs14035 in the RAN gene (95% CI: 1.601–14.925; P=0.002), the T/T genotype of rs9623117 in the TNRC6B gene (95% CI: 0.03–0.608; P=0.003), and the A/A genotype of rs3742330 in the Dicer gene (95% CI: 1.223–3.178; P=0.005) were observed in GC patients. These results indicate that the carriers of these alleles are susceptible to GC (Table 3).
Table 3

miR-SNPs frequency difference between patients with gastric cancer and controls

VariantsGeneGenotypeCaseControlP-valueOR95% CI
rs11077XPO5A/A1191230.9531.0210.511–2.040
A/C + C/C1819
rs14035RANC/C86350.0024.8881.601–14.925
C/T + T/T51107
rs3742330DicerA/A75540.0051.9711.223–3.178
A/G + G/G6288
rs9623117TNRC6BT/T1351280.0030.1350.03–0.608
C/T + C/C214
rs197412GEMIN3T/T65600.3831.2340.769–1.979
C/T + C/C7282
rs2740348GEMIN4G/G1101150.9281.0270.572–1.845
C/G + C/C2729

Abbreviations: CI, confidence interval; miR-SNP, microRNA-related single-nucleotide polymorphism; OR, odds ratio.

Discussion

The miR-SNPs in RAN, Dicer, and TNRC6B were associated with the carcinogenesis of GC in our analysis. To our knowledge, this is the first report to indicate that the SNP sites in the miRNA processing machinery genes have predictive value for determining the incidence of GC. RAN is a member of the Ras superfamily of GTPases and is essential for the translocation of pre-miRNAs from the nucleus to the cytoplasm. XPO5 binds to pre-miRNA and RAN-GTPase in the nucleus (via the XPO5RAN GTP–pre-miRNA heteroternary complex) to mediate the nuclear export of pre-miRNA in a RAN GTP-dependent manner.31 Disruption of pre-miRNA nucleocytoplasmic transport would impair the production of mature miRNAs in cancer cells. The fact that RAN is overexpressed in some cancer cell lines, including colon cancer, implies its role in tumor transformation; moreover, RAN was reported to suppress the activation of C-Jun-NH2-kinase and inhibit the apoptosis induced by an anticancer drug.32,33 The rs14035 located in RAN might alter RAN expression, so as to initiate carcinogenesis by modulating the production of mature miRNAs. Dicer was also implicated in the oncogenic process of several cancers, but the data were controversial; downregulated Dicer expression has been identified in lung cancer, ovarian cancer, nasopharyngeal cancers, breast cancer, and esophageal cancer, whereas upregulated Dicer expression was found in lung adenocarcinoma, colorectal cancer, and primary cutaneous T-cell lymphomas.27,34–40 The mechanism underlying how the rs3742330 SNP modified the GC risk remains unclear; the location of this SNP in the 3′-untranslated region of Dicer might potentially influence the stability and expression of the gene. TNRC6B (or KIAA1093), localized on the mRNA-degrading cytoplasmic P bodies, is one of the three Argonaute-interacting protein paralogs in vertebrates. They assist in the formation of miRNA ribonucleoparticles or miRISCs, so as to mediate miRNA-guided mRNA cleavage.16,41–44 The T/T genotype of rs9623117 in TNRC6B has been found to be associated with prostate cancer risk. Alterations in TNRC6B gene expression due to genetic variations of rs9623117 might perturb the levels of miRNA species normally under its control, thus contributing to carcinogenesis.45 The frequency distribution of these six SNPs and the patients’ clinical characteristics (including their sex, age, and tumor stage) do not appear to be associated, as determined by our analysis (data not shown). These six miR-SNPs were analyzed for their relationship with postoperative survival in 95 patients for whom 3-year follow-up data were available. It was found that rs2740348 showed a marginally statistically significant association with survival (P=0.06; our unpublished data). These findings should be validated with a larger sample size. Although the results of this study require further validation among a larger GC cohort, as well as in laboratory-based functional studies, our data are encouraging because they demonstrate that miR-SNPs can be used to predict the risk for developing GC.
  45 in total

1.  High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.

Authors:  Julia Valencak; Katharina Schmid; Franz Trautinger; Werner Wallnöfer; Leonhard Muellauer; Afschin Soleiman; Robert Knobler; Andrea Haitel; Hubert Pehamberger; Markus Raderer
Journal:  J Dermatol Sci       Date:  2011-09-08       Impact factor: 4.563

2.  The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma.

Authors:  Xiaofang Guo; Qianjin Liao; Pan Chen; Xiayu Li; Wei Xiong; Jian Ma; Xiaoling Li; Zhaohui Luo; Hailin Tang; Min Deng; Yin Zheng; Rong Wang; Wenling Zhang; Guiyuan Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-28       Impact factor: 4.553

Review 3.  Transcription and processing of human microRNA precursors.

Authors:  Bryan R Cullen
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

4.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

Review 5.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

6.  Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.

Authors:  V Boni; R Zarate; J C Villa; E Bandrés; M A Gomez; E Maiello; J Garcia-Foncillas; E Aranda
Journal:  Pharmacogenomics J       Date:  2010-06-29       Impact factor: 3.550

7.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

8.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

9.  Functional dissection of the human TNRC6 (GW182-related) family of proteins.

Authors:  David Baillat; Ramin Shiekhattar
Journal:  Mol Cell Biol       Date:  2009-05-26       Impact factor: 4.272

10.  MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1.

Authors:  Q Wu; Z Yang; Y An; H Hu; J Yin; P Zhang; Y Nie; K Wu; Y Shi; D Fan
Journal:  Cell Death Dis       Date:  2014-03-27       Impact factor: 8.469

View more
  18 in total

1.  A polymorphism at the microRNA binding site in the 3'-untranslated region of C14orf101 is associated with the risk of gastric cancer development.

Authors:  Cuiju Wang; Yufei Zhao; Yanming Ming; Shengnan Zhao; Zhanjun Guo
Journal:  Exp Ther Med       Date:  2016-07-13       Impact factor: 2.447

Review 2.  Single nucleotide polymorphisms in piRNA-pathway genes: an insight into genetic determinants of human diseases.

Authors:  Jyoti Roy; Kalyani Anand; Swati Mohapatra; Rojalin Nayak; Trisha Chattopadhyay; Bibekanand Mallick
Journal:  Mol Genet Genomics       Date:  2019-10-14       Impact factor: 3.291

3.  Genetic polymorphisms of microRNA machinery genes predict overall survival of esophageal squamous carcinoma.

Authors:  Cuiju Wang; Hailing Dong; Haiyan Fan; Jianhua Wu; Guiying Wang
Journal:  J Clin Lab Anal       Date:  2017-12-11       Impact factor: 2.352

Review 4.  Polymorphisms in mucin genes in the development of gastric cancer.

Authors:  Rong Wen; Fang Gao; Cheng-Jiang Zhou; Yan-Bin Jia
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

5.  Genetic variants in the MicroRNA biosynthetic pathway Gemin3 and Gemin4 are associated with a risk of cancer: a meta-analysis.

Authors:  Wenbo Zhu; Jun Zhao; Jieyu He; Daxun Qi; Lina Wang; Xu Ma; Pei Liu
Journal:  PeerJ       Date:  2016-03-15       Impact factor: 2.984

6.  Association of GEMIN4 gene polymorphism and the risk of cancer: a meta-analysis.

Authors:  Nan Wu; Xiaowei Zhang; Jinlong Tian; Shuang Yu; Ying Qiao
Journal:  Onco Targets Ther       Date:  2017-11-02       Impact factor: 4.147

7.  Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer.

Authors:  Osmel Companioni; José Miguel Sanz-Anquela; María Luisa Pardo; Eulàlia Puigdecanet; Lara Nonell; Nadia García; Verónica Parra Blanco; Consuelo López; Victoria Andreu; Miriam Cuatrecasas; Maddi Garmendia; Javier P Gisbert; Carlos A Gonzalez; Núria Sala
Journal:  PLoS One       Date:  2017-04-25       Impact factor: 3.240

8.  Variation in the Dicer and RAN Genes Are Associated with Survival in Patients with Hepatocellular Carcinoma.

Authors:  Mi Na Kim; Jung Oh Kim; Seung Min Lee; Hana Park; Ju Ho Lee; Kyu Sung Rim; Seong Gyu Hwang; Nam Keun Kim
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

9.  MicroRNA biogenesis pathway genes polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Jieyu He; Jun Zhao; Wenbo Zhu; Daxun Qi; Lina Wang; Jinfang Sun; Bei Wang; Xu Ma; Qiaoyun Dai; Xiaojin Yu
Journal:  PeerJ       Date:  2016-12-07       Impact factor: 2.984

10.  Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population.

Authors:  Xingbo Song; Huiyu Zhong; Qian Wu; Minjin Wang; Juan Zhou; Yi Zhou; Xiaojun Lu; Binwu Ying
Journal:  Oncotarget       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.